Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
Toxins · 2025
DOI: 10.3390/toxins17030145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Pei Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichua…. Hauptthemen laut MEDLINE: Aristolochic Acids, Acute Kidney Injury, Guanidines, Benzamidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Provincial Department of Science and Technology, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Acute kidney injury (AKI) is a condition with a poor prognosis, exacerbated by the lack of effective therapeutic options and inadequately understood underlying mechanisms. Glycosylation, a post-translational modification of proteins, is essential for maintaining protein stability and function, and its dysregulation leads to protein misfolding and amyloid aggregation. Glycosylation dynamics are implicated in several pathologies, including inflammation, cancer, and AKI, highlighting the therapeutic potential of regulating glycosylation and preventing aggregation in AKI treatment. This study investigates the effect of nafamostat mesylate (NM) on protein glycosylation and amyloid aggregation in vivo. Using optical spectroscopy and other analytical techniques, we demonstrate that NM restores glycosylation levels and inhibits protein aggregation in aristolochic-acid-induced acute kidney injury. The mechanism likely involves enzymatic modulation that corrects hypoglycosylation and prevents amyloid aggregation, promoting proper protein folding and enhancing its stability. These findings suggest that NM may provide a novel therapeutic strategy for AKI and other glycosylation-related diseases, underscoring the potential for early intervention and treatment of these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sic…
- Co-Construction Collaborative Innovation Center for Chinese Medicine Resources Industrialization by Shaanxi & Education Ministry, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
- Haisco Pharmaceutical Group Co., Ltd., Chengdu 611130, China.
Förderung
- Sichuan Provincial Department of Science and Technology
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Xie, P., Liu, H., Huo, X., Chen, J., Li, Y., Huang, Y., & Yin, Z. (2025). Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury. Toxins. https://doi.org/10.3390/toxins17030145
Vancouver
Xie P, Liu H, Huo X, Chen J, Li Y, Huang Y, et al. Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury. Toxins. 2025. doi:10.3390/toxins17030145
BibTeX
@article{Xie2025,
author = {Xie, Pei and Liu, Huijun and Huo, Xingli and Chen, Junlong and Li, Yu and Huang, Yu and Yin, Zongning},
title = {Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17030145}
}
EUVIMED